New Delhi [India], July 19 (ANI): Alembic Pharmaceuticals said its partner NATCO Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Olaparib Tablets in 100 mg and 150 mg strengths, a generic equivalent of AstraZeneca’s Lynparza tablets.
The approval is for the indication covered under the approved labelling of the reference listed drug. Alembic Pharmaceuticals will distribute the product in the United States, while NATCO Pharma will manufacture the tablets.
The product is expected to address a significant market opportunity in the US. Olaparib Tablets in the 100 mg and 150 mg strengths had an estimated market size of around USD 1.4 billion for the 12 months ended March 2026, according to IQVIA data cited by the company.
However, the commercial launch timeline remains subject to the ongoing Paragraph IV litigation related to the product. The tentative approval therefore marks a regulatory milestone, while the outcome of the litigation will remain an important factor for the product’s market entry.
Olaparib is a PARP inhibitor used in the treatment of certain cancers and is marketed as Lynparza by AstraZeneca. The approval strengthens Alembic’s product pipeline in the US generic pharmaceutical market and expands its portfolio of products targeting large-market opportunities.
Alembic Pharmaceuticals’ cumulative tally of USFDA ANDA approvals has risen to 244, comprising 224 final approvals and 20 tentative approvals.
Alembic Pharmaceuticals is a vertically integrated research and development-focused pharmaceutical company with operations spanning generic medicines and branded generics. The company manufactures and markets generic pharmaceutical products globally and operates research and manufacturing facilities approved by regulatory authorities in developed markets, including the USFDA.
The latest approval comes as Indian pharmaceutical companies continue to expand their presence in the US generic market through partnerships, complex products and large-market opportunities. For Alembic, the approval provides another potential growth avenue, although the ongoing litigation and the eventual commercial launch remain key monitorables. (ANI)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
